Mary Bates, PhD

Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.

Treated immune cells function properly to kill more bacteria, depending on the treatment and the bacteria.

A protein that triggers an imbalance of mucous and ciliated cells in patients with chronic lung disease could be a target for treatments to restore airways.

Care transition plans aren’t just for kids with congenital conditions anymore. Could your practice benefit from a proactive transition plan for all patients?